The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|77|3-4|224-230

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.3-4, 2009-09, pp. : 224-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 210-213

Karger

Access to resources Recommend Favorite

Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 101-109

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite